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ABSTRACT 
 
 Influenza A virus (IAV) is an important respiratory pathogen of swine in the United 
States. Whole virus, inactivated vaccines are a common method used to control infection and 
clinical disease. However, homologous IAV vaccine antibody responses are rarely evaluated 
in the field and many influenza serological evaluations are lacking. New replacement gilts 
are an unstudied population in breeding farms and have been shown to affect viral ecology 
through introducing new IAV or lacking protection against resident viruses. Serological 
evaluations are uncommon in the current literature and could prove important in evaluating 
vaccine responses. This study sought to address all of these points by conducting a one-year 
longitudinal serological evaluation of replacement gilts on twelve different United States 
farms. 
 The study was performed by acquiring serum samples from each farm at four time 
points over the course of a year. The serum samples were evaluated using nucleoprotein 
enzyme-linked immunosorbent assay and hemagglutination inhibition assay. The 
hemagglutination inhibition assay was performed using homologous vaccine antigens based 
on each farm-specific vaccination protocol and six representative viruses, which were 
selected due to their predominance in the US swine population and representing the major 
antigenic clades and genetic clusters. 
 The study found that a large number of gilts were IAV antibody negative when 
delivered to the breeding farm or at the age when gilts are breed for production. This 
suggests new replacement gilts might be susceptible to endemic IAV and may help maintain 
endemic infections on a farm. It was also found that the levels of vaccine-induced antibody 
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were highly variable between farms and overtime on the same farm. This variability in the 
number of gilts demonstrating homologous vaccine antibody responses suggests gaps in 
protection may occur which allows for either the maintenance of endemic viruses within a 
herd or creates a risk of lateral infection with new or emerging IAV from outside sources. 
This study supports the idea of increased serological surveillance to evaluate vaccine 
antibody responses that may correlate with efficacy and help determine the magnitude of 
protection on a farm or reasons why vaccines appear to fail if antibody responses are lacking. 
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CHAPTER 1. INTRODUCTION  
 
Statement of the Problem 
 Replacement gilts are an important subpopulation of swine in breed-to-wean production 
systems replacing approximately 50% of the breeding herd each year in the US. Therefore, new 
gilts entering the breeding herd may negatively influence disease dynamics in a production 
system including IAV. Therefore, it is important to understand the IAV status of new 
replacement gilts, including the presence of IAV antibody, prior to entry into the breeding herd. 
In addition, protecting new gilts against endemic IAV through vaccination is an important 
biosecurity method incorporated into isolation and acclimation protocols. Evaluating the IAV 
vaccine antibody response in new gilts may help identify potential reasons for perceived vaccine 
failures and suggest areas that may help improve our methods to control IAV in breed-to-wean 
production systems. 
 
Objectives 
 The first objective of this field study was to evaluate the presence of influenza A virus 
(IAV) antibody in a cohort new replacement gilts selected from twelve different swine farrow-to-
wean production systems in the United States (US) coinciding with isolation/acclimation and 
prior to IAV vaccination. The second objective was to conduct a longitudinal study to evaluate 
the IAV vaccine antibody response for approximately one year that included the post-vaccination 
and post-integration time points using a subset of the same replacement gilts. Replacement gilts 
were the target subpopulation due to their potential influence on the IAV dynamics in breeding 
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herds that may include introducing new IAV, supporting endemic infections, or representing an 
IAV immunologically naïve subpopulation within the production system. 
 
Thesis Organization 
 This thesis is organized into five chapters. The first chapter is a general introduction to 
the thesis. The second chapter consists of a literature review summarizing IAV with an overview 
of serology data available for swine in North America. The third chapter evaluates the IAV 
antibody status of non-vaccinated, new replacement gilts of breeding age. The fourth chapter 
evaluates the presence and magnitude of the IAV antibody in a subset of the same gilts for 
approximately one year after IAV vaccination and integrating into the main breeding herd. The 
fifth chapter is a summary of the IAV antibody data that was observed during the study. 
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CHAPTER 2. LITERATURE REVIEW 
 
Introduction 
Influenza A virus (IAV) is a primary cause of respiratory disease in swine worldwide and 
can be a source of zoonotic infection in humans (Vincent et al., 2008). Currently, three major 
subtypes of IAV, H1N1, H1N2, and H3N2, co-circulate in North American swine (Vincent et al., 
2008). The predominant surface proteins, hemagglutinin (HA) and neuraminidase (NA), are 
responsible for viral attachment and release in permissive cells, respectively, and provide partial 
restriction of their host range. The HA protein represents considerable genetic and antigenic 
diversity complicating the ability to prevent infection and clinical disease using traditional 
biosecurity practices and commercial or farm-specific inactivated vaccines (Vincent et al., 2008). 
Currently the HA of the H1 subtype consists of eight phylogenetic clades that includes: α, β, γ, 
γ2, δ-1a, δ-1b, δ-2, and pandemic (Vincent et al., 2014). There are eight H3 phylogenetic clusters 
as follows: cluster IV, IV-A, IV-B, IV-C, IV-D, IV-E, IV-F, and human-like (Kitikoon et al., 
2013). The most prominent clades in North America are the H1 γ, H1 δ-2, and H3 cluster IV-A 
(Vincent et al., 2017). Influenza vaccines in swine have become more common, particularly in 
breeding swine, to prevent clinical disease but do not prevent infection (Corzo et al., 2012). A 
complication of increased vaccine use is the difficulty interpreting IAV serology outcomes. 
Serology tests are unable to differentiate between antibody induced by natural infection, IAV 
vaccines, and maternal antibody that can be passively transferred from naturally infected or 
vaccinated dams (Loeffen et al., 2003). Historically, the hemagglutination inhibition (HI) assay 
was the gold standard for detecting IAV antibody and determination of the HA subtype (Yoon et 
al., 2004). However, increasing IAV genetic and antigenic diversity has complicated our ability 
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to effectively use HI assays to evaluate IAV antibody responses in swine. Recently, the use of 
enzyme-linked immunosorbent assays (ELISA) based on the conserved nucleoprotein (NP) 
antigen has become more common for detecting IAV immune responses although this assay also 
does not distinguish between natural infection and vaccine antibody (Ciacci-Zanella et al., 2010; 
Goodell et al., 2016). Additionally, some new vaccine platforms, like replicon particle vaccines, 
do not induce an NP antibody response and thus cannot be evaluated using the NP ELISA 
(Vander Veen et al., 2012). Collectively, the diverse IAV ecology circulating in swine has 
altered how veterinarians and animal health officials use serology tests to answer specific 
diagnostic questions and interpret the results.  
Replacement gilts have become an important subpopulation in breed-to-wean farms that 
may influence the disease dynamics in a production system. Disease monitoring is often minimal 
in new replacement gilts and limited to detection of porcine reproductive and respiratory 
syndrome virus (PRRSV). New gilts may impact the epidemiology and ecology of IAV in 
breeding herds based on their status upon entry to the farm. Monitoring the presence and 
magnitude of IAV antibody as well as the virus may be an important biosecurity method in the 
overall control of influenza in breed-to-wean production systems. 
 
Influenza A Virus Classification And Genome Organization 
Influenza A Virus, a member of the Orthomyxoviridae family, is a negative sense, single 
stranded, RNA virus (Zell et al., 2013). The virus contains an envelope and eight genome 
segments that code for 11-12 proteins (Sandbulte et al., 2015; Zell et al., 2013). The HA and NA 
proteins are encoded on Segment 4 and 6, respectively, of the viral genome (Lorusso et al., 
2011). Influenza A viruses are subtyped based on classification of their HA and NA genes. 
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Currently, 18 HA subtypes and 11 NA subtypes have been detected circulating in nature, but 
only a small subset are endemic to swine (Sandbulte et al., 2015; Urbaniak and Markowska-
Daniel, 2014). The additional genetic segments comprising the internal structural and non-
structural proteins are as follows: Segment 1 = Polymerase Basic 2 (PB2), Segment 2 = 
Polymerase Basic 1 (PB1), Segment 3 = Polymerase Acidic (PA), Segment 5 = Nucleoprotein 
(NP), Segment 7 = Matrix 1 (M1) and Matrix 2 (M2), Segment 8 = Non-structural 1 (NS1) and 
Non-structural 2/Nuclear Export Protein (NS2/NEP) (Lorusso et al., 2011).  
The HA protein is primarily responsible for binding to host cells, internalization of the 
virus, and endosomal membrane fusion once inside the permissive host cell (Steinhauer, 1999). 
Internalization and membrane fusion are accomplished by cleavage of the HA protein which 
requires host proteases. The availability of proteases to cleave the HA protein determines host 
and tissue specificity for IAV (Matrosovich et al., 2009). For example, IAV is able to target the 
gastrointestinal tract in avian species due to the presence of proteases in enterocytes with the 
ability to cleave the HA protein (Thacker and Janke, 2008). In contrast, mammals contain 
proteases capable of cleaving the HA protein that are exclusive to the respiratory tract (Janke, 
2014; Lipatov et al., 2008). The HA protein targets specific receptors by binding to sialic acid 
moieties located on the surface of host cells. Mammalian influenza viruses target α2-6 sialic acid 
moieties and avian influenza viruses target α2-3 sialic acid moieties (Matrosovich et al., 2009; 
Paulson, 1985; Sandbulte et al., 2015). The HA protein is also the target of neutralizing 
antibodies that can prevent attachment to the host cell receptor or inhibit cleavage of the HA 
protein once inside the endosome, thus preventing membrane fusion, viral entry, and subsequent 
replication (Van Reeth and Ma, 2013; Wiley et al., 1981). 
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The NA protein is responsible for releasing nascent virus from the host cell by cleaving 
the attachment between sialic acid residues and HA protein using an intrinsic sialidase (Reperant 
et al., 2012; Urbaniak and Markowska-Daniel, 2014). Mutations in the NA gene can alter viral 
virulence by affecting transmission through the ability of IAV to exit host cells (Janke, 2014; 
Reperant et al., 2012). The inability to successfully exit an infected cell causes the virus to 
become vulnerable to other innate immune responses, such as apoptosis and phagocytosis, as the 
virus becomes trapped within the dying cell instead of escaping to find a new host cell (Reperant 
et al., 2012). 
The polymerase genes, PB1, PB2, and PA, are responsible for replication of the viral 
genome and hijacking the host cellular machinery. All three proteins work together to form the 
viral RNA dependent RNA polymerase (Basler and Aguilar, 2008; Janke, 2014). PB1 is the 
catalyst for polymerization whereas PB2 and PA are responsible for stealing the 5’ cap of host 
mRNA (Janke, 2014; Urbaniak and Markowska-Daniel, 2014). All three polymerase subunits are 
packaged with the viral nucleoprotein as a complex and become activated once the virus has 
entered a new host cell (Basler and Aguilar, 2008; Janke, 2014).  
The non-structural protein I (NS I) interferes with host cell signaling that inhibits the 
production of antiviral cytokines including Interferon α and β, Tumor Necrosis Factor α, and 
Interleukin 6 (Basler and Aguilar, 2008; Janke, 2014).  
The M2, or Matrix 2, is an ion channel protein incorporated into the viral envelop. After 
the virus is endocytosed by the host cell, the virus is placed in an endosome which is acidified by 
host ion pumps. The M2 protein then pumps these ions into the viral capsid to lower the pH 
(Samji, 2009). Once the pH is lowered beyond a threshold, it triggers the release of the viral 
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genome from the viral M1 proteins and the viral RNPs are released into the cytoplasm. Once in 
the cytoplasm, the viral genome begins replication (Sandbulte et al., 2015).  
All IAV genes have been shown to influence virulence, either individually or in 
combination with one another (Janke, 2014). A functional virus contains eight ribonucleoprotein 
(RNP) complexes, which is a composite of the viral RNA and NP. The eight RNPs are 
encapsulated together with the M1 protein in a viral capsid (Samji, 2009). The capsid is 
subsequently covered by the viral envelope, which is derived from the host cell membrane and 
includes the HA, NA, and M2 proteins (Lee and Saif, 2009; Samji, 2009). A single RNP 
complex consists of an individual RNA genome segment that encodes one or more viral proteins, 
the viral NP, which binds to and protects the viral RNA, and the viral polymerase complex 
consisting of the PA, PB1, and PB2 proteins (Lee and Saif, 2009). Upon entry, the RNP 
complexes are released into the host cell when the host and viral membrane fusion occurs. The 
RNP complexes contain nuclear localization signals and begin viral genome replication upon 
reaching the nucleus (Reperant et al., 2012).  
Influenza viruses change and evolve over time due to two main mechanisms: genetic drift 
and genetic shift (Zell et al., 2013). Genetic drift results from the accumulation of small point 
mutations in key regions of the HA gene can alter the antigenic properties of the virus (Zell et al., 
2013). Genetic shift is the result of a process known as reassortment. Reassortment can 
occasionally occur when two or more strains of IAV co-infect a single host cell and then 
exchange one or more genome segments (Urbaniak and Markowska-Daniel, 2014). Reassortment 
between any of the viral genes can lead to the development of novel strains with altered host 
specificity and virulence characteristics (Sandbulte et al., 2015; Zell et al., 2013). Many swine 
viruses are the result of previous reassortment between human or avian viruses with endemic 
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swine viruses which may produce a novel and virulent virus that is easily transmitted in a swine 
population if cross-protective immunity is partial or absent (Brown et al., 1998; Diaz et al., 2017; 
Vincent et al., 2009; Winkler and Cheville, 1986). Since each of the eight viral gene segments 
act independently, there are 256 possible different genetic combinations that could possibly 
result from two different strains of IAV reassorting. Fortunately, many reassortant viruses fail to 
establish endemic infections within a swine population (Urbaniak and Markowska-Daniel, 2014).  
 
Epidemiology 
North American IAV Genetic Linages  
Surveillance of swine herds is performed through a passive process by the United States 
Department of Agriculture using porcine submissions to the National Animal Health Laboratory 
Network (NAHLN) member diagnostic laboratories (Sandbulte et al., 2015). Veterinarians 
voluntarily submit diagnostic samples from swine with clinical respiratory disease to diagnose a 
cause. If IAV is detected, subtyping and virus isolation are performed with sequencing of 
successful virus isolates. The viral isolate and data are then submitted to the National Veterinary 
Services Laboratory (NVSL) repository that is maintained for public use. The population 
dynamics of IAV-S over the last several years have been monitored using the data from the 
USDA surveillance program (USDA, 2017).   
Reports based on the USDA data have determined that there are 16 distinct H1 and H3 
genetic clades of IAV in US swine (Anderson et al., 2015; Kitikoon et al., 2013; Vincent et al., 
2014; Vincent et al., 2017). The classical H1N1 virus is thought to have originated from the 1918 
Spanish Flu human pandemic, which spilled-over into North American swine. The virus 
remained antigenically stable in swine for 80 years, from 1918 to 1998, when the H3 subtype 
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became established in swine (Sandbulte et al., 2015; Vincent et al., 2008). Classical H1N1 was 
first diagnosed in 1919 and later isolated in the 1930s (Shope, 1931). Currently, the H1 subtype 
has emerged into multiple phylogenetic clusters in North America designated as α, β, γ, γ-2, δ-
1a, δ-1b, δ-2 and the H1N1 pandemic (H1pdm09) (Lorusso et al., 2013; Vincent et al., 2009). 
The α, β, γ, and γ-2 clades are descendants from the classical H1N1 and typically have swine 
origin HA and NA genes (Lorusso et al., 2011; Vincent et al., 2014). The δ-1a, δ-1b and δ-2 H1 
viruses descended from human-origin viruses (Anderson et al., 2013; Sandbulte et al., 2015). The 
γ and δ H1 clades have virtually replaced the α and β H1 clades in North American swine (Chen 
et al., 2012).   
In the 1990s, a new virus of the H3 subtype emerged in US swine. The H3 became 
established in swine from a reverse zoonotic event where a human seasonal H3 crossed the 
species barrier and infected swine (Zhou et al., 1999). These reverse zoonotic events may occur 
when humans and swine are in close proximity, such as employees at swine farms or exhibition 
shows and fairs (Feng et al., 2013). The 1998 H3N2 virus contained the triple reassortant internal 
gene (TRIG) cassette and has since produced many reassortant progeny IAV (Lorusso et al., 
2011; Vincent et al., 2014). The TRIG cassette was the result of a reassortment event between 
human, avian, and swine lineage viruses that resulted in the following: human origin PB1 gene; 
avian origin PA and PB2 genes; swine origin NS, NP, and M genes (Vincent et al., 2008; Webby 
et al., 2000). The TRIG cassette has the ability to acquire a variety of HA and NA genes in swine 
IAV. Currently, the TRIG is detected in all contemporary strains of both H1 and H3 subtypes 
(Lorusso et al., 2013; Vincent et al., 2008).  
Spillover events from human viruses have repeatedly influenced the genetic diversity of 
influenza A viruses in swine (IAV-S). In 2005, a reverse zoonosis event occurred involving the 
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H1 subtype, which lead to the development of the δ-cluster IAV (Lorusso et al., 2013). The δ 
cluster has become highly prevalent in North America and can be found in US and Canadian 
swineherds (Choi et al., 2002b; Karasin et al., 2006). The δ-cluster can be subdivided into the δ-1 
and δ-2 clusters with putative δ-1a and δ-1b clades that have become established (Anderson et 
al., 2015; Choi et al., 2002a). The δ-1 and δ-2 clusters are the result of a different reverse 
zoonotic event and each prefers a different NA subtype; δ1 prefers N2 subtype and δ2 prefers N1 
subtype (Lorusso et al., 2013; Vincent et al., 2009).  
A more recent phylogenetic cluster to emerge is the H1pdm09. The H1pdm09 is a swine-
lineage reassortant IAV that was first identified in humans in Mexico in 2009 (Mena et al., 2016; 
York and Donis, 2013). The virus quickly spread worldwide. The H1pdm09 has been detected in 
most major swine populations, such as the US, China, Argentina, and Germany, and is 
worldwide (Dibárbora et al., 2013; Liu et al., 2011; Nelson et al., 2015a; Nelson et al., 2015b). It 
is still unclear where the virus originally evolved. Antigenic and genetic characterizations have 
failed to pinpoint the origins of the virus due to gaps in the global surveillance data (Vincent et 
al., 2014; York and Donis, 2013). It has been theorized that the IAV developed from precursor 
viruses in Mexico with subsequent reassortment with IAV from Asia that were present in 
imported swine (Mena et al., 2016). The pdm09 virus contained six gene segments from a North 
American triple reassortant swine-lineage (PB2, PB1, PA, HA, NP, and NS) and two gene 
segments from a European swine-lineage (NA and MP) (York and Donis, 2013). The H1pdm09 
virus has reassorted with many endemic strains in swine to generate novel reassortant viruses 
(Kong et al., 2015). The H1pdm09 strain matrix (M) gene is currently detected in all US strains 
of IAV-S regardless of subtype or cluster (Kong et al., 2015; Nelson et al., 2015a; Sandbulte et 
al., 2015).  
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One of the most recent human to swine spillover events was the emergence of a novel 
human-like H3 (H3 hu-like) in swine from the 2012 season (Rajão et al., 2015). Veterinary 
diagnostic laboratories began detecting the H3 hu-like during the 2012 season and have 
consistently recovered a small number each of the following years (USDA, 2017). In 2015, a 
study was performed to analyze the phylogenetic relationships of two isolates of the novel H3 
hu-like (Rajão et al., 2015). It was determined that the HA gene was related to the 2010 human 
seasonal IAV, the NA was also derived from the 2002 human seasonal IAV, and the internal 
genes were a mix of the TRIG constellation and H1pdm09 internal genes (Rajão et al., 2015). 
Interspecies transmission events continue to occur and lead to greater genetic diversity in IAV-S 
(Nelson et al., 2012).  
 
Clinical Features  
Traditionally, IAV-S is a seasonal disease that peaks during the cold winter months (Liu 
et al., 2016). Currently, IAV-S infections can be detected throughout the year and in all age 
groups of swine due to the increased genetic diversity of different strains of IAV (Vincent et al., 
2014). Influenza has high morbidity, upwards of one hundred percent, and low mortality, often 
less than one percent. These factors can vary between strains and within populations (Vincent et 
al., 2014). The virus is primarily spread through pig-to-pig contact via the nasopharyngeal route. 
The virus is shed from the nose or mucus and spreads via aerosols and droplets (Brown, 2000).  
Typical clinical signs include coughing, sneezing, loss of appetite, nasal congestion, nasal 
discharge, and lethargy. Symptoms typically begin 1-2 days post infection and continue for 7-10 
days, with viral clearance within 2 weeks or less with some variation (Brown, 2000; Liu et al., 
2016). High fevers are common during the second and third days post infection, but often abate 
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as more typical clinical signs develop around the fourth or fifth day post infection (Janke, 2013). 
The disease has a short incubation time of 2-3 days and as a result, whole herds will often 
contract the disease within a span of a few days depending on population immunity (Janke, 
2013). Infected swine do not always demonstrate clinical signs suggestive of influenza. Many 
pigs can have a sub-clinical infection where they shed virus but do not have signs of distress or 
disease (Corzo et al., 2013). As a result, clinical observations are not always a reliable method to 
diagnose influenza in a swine population (Vincent et al., 2014). Virus shedding typically begins 
1-2 days post infection and can continue for up to one week, which also contributes to the rapid 
spread of the virus throughout a herd. One study, performed in Spain during 2008/09, reported 
over 90% of farms were positive for IAV-S via serological tests but only about 9% of those 
farms reported observing clinical signs of disease in their swine (Simon-Grifé et al., 2011).  
IAV primarily targets the respiratory tract in swine and viral replication and tissue 
damage occur in the epithelium of the respiratory tract (Janke, 2014). The virus infects epithelial 
cells from the nasal mucosa to the alveoli of the lungs. In the lungs, it causes mild to severe 
microscopic lesions that result in necrotizing bronchitis and bronchiolitis (Janke, 2014; Winkler 
and Cheville, 1986). Within the first 48 hours post infection, the epithelium begins to slough off 
as cells die due to viral replication and immune-mediated damage (Janke, 2014). Viral 
replication directly causes cell death by suppressing host cellular functions and inducing cell 
lysis. Cell death induces an inflammatory response due to cytokine mobilization, which causes 
further damage to the tissues in the lungs (Oldstone et al., 2013). 
The immune response to influenza infection can be divided into two steps: the innate and 
the adaptive responses. The innate response starts when immune cells recognize broad features 
that are common to viral pathogens, such as double strand RNA replication intermediates 
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(Yoneyama et al., 2004). During the first 24 hours post infection, neutrophils migrate to the site 
of infection and begin secreting pro-inflammatory cytokines and chemokines. After 24 hours 
post infection, macrophages begin to replace neutrophils as the primary immune cell (Janke, 
2014). Macrophages and dendritic cells engulf viruses, or virus infected cells, and then present 
the antigens to adaptive immune cells in the lymph nodes (Braciale et al., 2012). During a 
cytokine storm, which is an over production of cytokines, vascular leakage and cell death may 
occur, which causes tissue damage (Janke, 2014). Cytokines and inflammation are necessary for 
viral clearance but the immune system must maintain a careful balance to prevent tissue damage 
that could impair lung function (Oldstone et al., 2013). If too much tissue damage occurs in the 
lung, it may lead to respiratory failure (Braciale et al., 2012). As a result, many immune cells 
also secrete anti-inflammatory compounds to modulate the host immune response. 
The adaptive immune response has two important components: humoral and cell-
mediated immunity. The humoral component involves induction of antibodies against specific 
proteins of the virus to prevent infection and transmission, also known as neutralizing antibodies 
(Waffarn and Baumgarth, 2011). Antibodies are produced by B-cells and target specific regions 
of viral proteins called epitopes (Sandbulte et al., 2015). The HA protein of IAV is the target for 
neutralizing antibodies (Sandbulte et al., 2015). After clearance of the virus, some B-cells mature 
into memory cells which can be rapidly induced during subsequent infections (Van Reeth and 
Ma, 2013). Antibody peaks at two to three weeks post infection and then slowly wanes over time 
(Larsen et al., 2000). The cell-mediated component involves mobilizing T-cells. Cytotoxic T-
cells are able to recognize and kill infected host cells that display viral proteins on their surface, 
which helps clear the virus from the body (McMichael et al., 1983; Sandbulte et al., 2015; Van 
Reeth and Ma, 2013).  
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Macroscopic lesions develop in the lung due to viral replication and immune responses 
resulting in tissue damage. These lesions are usually most prominent in the cranioventral 
portions of the lung and can range from 10% to upwards of 40% of the pulmonary parenchyma 
depending on the severity of the infection (Janke, 2013). The tissue damage is often multifocal, 
meaning areas of lung damage can be adjacent to unaffected tissue, and are scattered throughout 
the cranioventral regions of the lung often in a lobular pattern. This is true at both the 
macroscopic and microscopic levels (Janke, 2013). By two weeks post infection, the virus is 
cleared and lung tissue has recovered from infection (Janke, 2013). Infection rarely causes 
permanent lung damage and recovery is often complete. However, severe infections complicated 
by secondary bacteria may cause permanent lung damage leading to decreased respiratory 
efficiency(Janke, 2014).  
 
Detection and Diagnosis 
 There are multiple methods available to demonstrate IAV infection in swine. One method 
is to directly isolate the virus from samples collected from animals, such as nasal swabs (Goodell 
et al., 2013). Another method is to test samples by PCR for the presence of viral genetic material, 
such as tissue samples, nasal swabs, and oral fluids (Zhang and Harmon, 2014). The caveat for 
both of these tests is that they require an active, acute infection in order to detect the virus. This 
is problematic since the window for influenza infection is short, about 7-10 days, and the 
window for viral shedding is even shorter, often only 3-5 days (De Vleeschauwer et al., 2009; 
Janke, 2013; Sandbulte et al., 2015; Vincent et al., 2006). Serological or antibody based assays 
are not as limited by the duration of infection. Once an animal has developed an immune 
response to a pathogen, it often lasts several weeks (Larsen et al., 2000; Markowska-Daniel et 
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al., 2011; Sreta et al., 2013). This allows for serological testing and evaluation long after an 
infection has occurred. As a result, serological assays are highly useful for detecting previous 
exposure on the individual level and the prevalence of exposure within a population, although it 
should be noted that vaccination can alter the antibody profile in vaccinated animals and thus 
complicate the interpretation of serological assays. 
 
Nucleoprotein Enzyme-linked Immunosorbent Assay  
 The Nucleoprotein Enzyme-linked Immunosorbent Assay (NP ELISA) is a diagnostic 
test used to detect antibodies against the nucleoprotein of IAV. The NP is a highly conserved 
protein across IAV strains thus the NP ELISA is a broad test used to detect influenza exposure in 
multiple species (Goodell et al., 2016). Anti-NP antibodies are not a measure of neutralizing 
ability, thus they do not correlate with protection. Natural infection and whole virus vaccination 
typically induce the development of anti-NP antibodies in swine (Ciacci-Zanella et al., 2010). 
The NP ELISA is able to detect anti-NP antibodies from natural infection, whole virus 
vaccination, and maternally derived antibodies that have been passively transferred to offspring 
from naturally infected or vaccinated dams (Ciacci-Zanella et al., 2010). This assay cannot 
provide information on subtype of the virus, nor can it differentiate between natural exposure, 
passive immunity, or vaccine antibody (Goodell et al., 2016).  
The Multi-Screen NP ELISA (IDEXX, Westbrook, ME) is a blocking ELISA and was 
used by Goodell et al., 2016, to evaluate antibody presence in swine serum (Goodell et al., 2016). 
The ELISA kit comes with a 96-well plate coated with IAV NP antigen based on a specific, 
conserved epitope in the protein. Serum is added to the plate and allowed to incubate, followed 
by a control antibody with a reactive tag. Post-incubation, a washing step is performed to remove 
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unbound antibody. Next, a chemical solution is added that reacts with the tag if present, and 
finally the plate is analyzed by a plate reader to determine the optical density of the color change. 
The values for each sample are compared to a negative and positive control and a 
Sample/Negative ratio is created. A 0.6 cut-off value is suggested by the manufacturer to 
determine positive and negative results. Values >0.6 are considered negative and results <0.6 are 
considered positive. Previous work has shown that the NP ELISA is very sensitive and specific 
(Goodell et al., 2016).  
 
Hemagglutination Inhibition Assay 
The hemagglutination inhibition (HI) assay is the preferred method for detecting and 
quantifying a protective antibody response to a specific strain of IAV (Dibárbora et al., 2013). 
The assay is relatively inexpensive and easy to perform as it only requires red blood cells (RBC), 
a reference virus, and the serum sample to be tested (Detmer et al., 2013). However, serum 
treatment is mildly time-consuming and necessary to remove non-specific serum agglutinins and 
inhibitors of agglutination (Kitikoon et al., 2014). The assay is performed by adding serum, 
treated and diluted 1:10, in a series of two fold dilutions in a 96-well plate, to which the virus 
antigen is added to each well, except the control well. The virus is diluted to a working 
concentration of 8 HA units (Detmer et al., 2013). The serum and virus are allowed to incubate 
for at least 30 minutes followed by the addition of 0.5% solution of RBCs to each well. 
Antibodies present in the serum will prevent RBC agglutination (Kitikoon et al., 2014). This 
results in a clear well with a compact “button” of RBCs at the bottom of the well. If no HI 
antibodies are present, the virus will bind to the sialic acid receptors on the surface of the RBCs 
and form a crosslinking lattice within the well. This lattice will produce a cloudy or hazy 
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appearance in the well known as agglutination (Kitikoon et al., 2014). The HI titer is the inverse 
of the highest dilution that displays inhibition. Titers greater than or equal to 40 are known to be 
protective and correspond to a 50% reduction in infection for an individual (Coudeville et al., 
2010; Hancock et al., 2009; Hobson et al., 1972).  
 
Serum Virus Neutralization Assay 
The serum virus neutralization assay (SVN) is another less common serological method 
of evaluating the functional antibody titer in a serum sample (Truelove et al., 2016). Serum is 
serially two-fold diluted in a 96 well plate and mixed with a known concentration of virus which 
is allowed to incubate for at least one hour before adding to a monolayer of MDCK cells and 
allowed to incubate for up to 48 hours (Gauger and Vincent, 2014). The cell culture plate is then 
evaluated for cytopathic effect (CPE) and wells without CPE are considered positive for 
neutralizing antibodies. Relative antibody titer is the reciprocal of the highest dilution without 
CPE (Detmer et al., 2013). SVN assays are useful because they demonstrate neutralizing 
antibodies to a variety of epitopes that can prevent viral infection of permissive cells (Gauger 
and Vincent, 2014). The SVN assay also requires more time, up to 48 hours compared to the HI 
assay, and reagents to perform the test, such as Madin-Darby Canine Kidney (MDCK) cells. The 
HI and the SVN titers are correlated in most cases for IAV (Truelove et al., 2016).  
 
Vaccination and Prevention 
The goal of a vaccine is to induce a protective immune response (Vincent et al., 2016). 
The protective immune response helps reduce viral shedding, severity of lung lesions, and 
influenza-like illness. Ideally, the immune response becomes a memory response that will be 
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protective against future infections if the virus is antigenically similar to the vaccine antigen 
(Chen et al., 2012). An ideal vaccine would provide complete protection and prevent shedding, 
lung lesions, and clinical signs of infection upon exposure to a homologous virus (Loving et al., 
2013). The challenge is to create a vaccine that extends that protection to heterologous IAV 
(Chen et al., 2012). There are several types of IAV vaccines including inactivated virus 
(commercial and autogenous), modified live virus / live attenuated virus, DNA based vaccines, 
subunit, and vectored (Chen et al., 2012).  
Inactivated whole virus and autogenous vaccines are killed versions of a virus 
administered to stimulate the immune system. The virus is rendered non-infectious by either 
chemical, thermal, or radiation based inactivation (Chen et al., 2012; Platt et al., 2011). This type 
of vaccine is often administered intramuscularly and induces a robust humoral response but has 
demonstrated limited cross protection against heterologous strains (Chen et al., 2012; Van Reeth 
and Ma, 2013; Vincent et al., 2016). The lack of cross protection may be due to limited mucosal 
immunity that is weakly primed with a vaccine administered only through the intramuscular 
route (Heinen et al., 2001; Van Reeth and Ma, 2013). Inactivated whole virus vaccines are often 
multivalent to induce broader protection but each additional virus added increases production 
costs (Van Reeth and Ma, 2013). Multivalent vaccines are necessary due to the increased viral 
diversity and poor cross-reactivity observed with inactivated vaccines (Lee et al., 2007). 
Autogenous vaccines are developed from an IAV isolated from the farm where the virus is 
currently circulating (Sandbulte et al., 2015). Theoretically, a vaccine developed from a farm-
specific viral isolate will provide superior protection compared to a commercial product that may 
not antigenically match the endemic strains on a farm. Autogenous vaccines have less regulatory 
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hurdles but restricted to use on the farm where the vaccine virus was isolated (Ma and Richt, 
2010).  
Live attenuated influenza virus (LAIV) vaccines or modified live virus (MLV) vaccines 
use an attenuated, or replication deficient, virus to prime the host immune response. A common 
method of attenuation is to mutate one of the viral genes, such as NS1 or one of the polymerase 
genes, which are responsible for altering host cytokine response or viral replication, respectively 
(Richt et al., 2006; Van Reeth and Ma, 2013). Without fully functional genes, the virus is unable 
to sustain an infection in a healthy host and only replicates a few times before the host immune 
system is able to clear the infection well before clinical disease would develop. Live attenuated 
vaccines are able to induce more cross-reactive immune responses compared to inactivated 
vaccines due to induction of both humoral and cell-mediated immune responses (Vincent et al., 
2007). One concern with live attenuated vaccines is the potential for reassortment with wild type 
viruses. Another concern is the potential for a live attenuated vaccine to revert back to a virulent 
virus (Chen et al., 2012). While both concerns are unlikely to occur, live attenuated vaccines 
have not been approved for use in swine until 2017 with the launch of the first LAIV vaccine in 
swine known as Provenza produced by Boehringer Ingelheim Vetmedica (Loving et al., 2013).  
DNA Vaccines are plasmids, which encode viral proteins that are injected into hosts to 
induce an immune response. Upon entering a host cell, the vaccine plasmid expresses the viral 
proteins encoded on the plasmid, thus priming the host immune system to those proteins (Chen et 
al., 2012; Kim and Jacob, 2009). DNA vaccines are non-infectious, can be made multivalent by 
adding additional viral genes, and induce both cellular and humoral immune responses (Dhama 
et al., 2008). The complex and laborious process of integrating a plasmid into a host cell is the 
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main drawback of DNA vaccines (Olsen, 2000). DNA vaccines also have short-lived immune 
responses and thus require periodic boosts to maintain protective levels.  
Subunit vaccines include the protein components of the virus which are administered 
with an adjuvant to induce an immune response, primarily humoral (Chen et al., 2012). The 
advantages of subunit vaccines are the ability to target the immune system against specific 
neutralizing antigens (HA protein), the ease of including multiple antigenic variants in one 
vaccine, and the proteins are non-infectious (Chen et al., 2012). The difficulty with this vaccine 
platform is producing the viral proteins, which often requires the use of a transgenic vector 
organism (D'Aoust et al., 2008). In addition, pure proteins are not immunogenic and an adjuvant 
is necessary to induce an adequate immune response (Chen et al., 2012). A key consideration is 
picking the correct antigenic target and presenting the protein in the correct conformation. If the 
correct antigen is selected and presented to the immune system, then a neutralizing antibody titer 
may be induced (Van Reeth and Ma, 2013).  
Vectored vaccines involve using molecular techniques to cut viral genes out of IAV and 
then implement them into another virus which is then used as the vaccine platform (Sandbulte et 
al., 2015). Vectors are rendered non-replicative or are already non-pathogenic in the swine host 
(Chen et al., 2012). The benefits of this method include induction of both the humoral and 
cellular immune response, the creation of multivalent vaccines using recombinant technology, 
and the potential to overcome maternal antibodies (Chen et al., 2012; Ma and Richt, 2010; 
Vander Veen et al., 2012). One of the complications of the vectored vaccine method is host 
immunity to the vector. Immunity can be preexisting, develop over time/vaccination, or be 
maternally derived (Chen et al., 2012). Another complication is the difficulty in making and 
maintaining a stable vector. 
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One issue for many vaccines is maternal antibodies, which can be passed from the mother 
to the offspring through the colostrum (Vincent et al., 2016). Maternal antibodies help protect 
young swine from natural infection but hinder attempts to prime the immune system since the 
maternal antibodies inactivate the vaccine antigen prior to inducing an immune response (Chen 
et al., 2012). This results in naïve swine when the maternal antibodies wane. Naïve swine are 
susceptible to any strain of IAV that are endemic to the farm (Thacker and Janke, 2008). This is 
undesirable because it leads to sickness in the swine and maintenance of the virus in the herd. An 
ideal vaccine platform would be able to circumvent interference from maternally derived 
antibodies and induce a protective immune response in young swine (Van Reeth and Ma, 2013). 
Currently, most commercial vaccines for swine in North America are multivalent 
inactivated virus vaccines (Loving et al., 2013; Vincent et al., 2016). Multivalent vaccines are 
usually necessary to induce broad protection since there are many genetic variants of IAV in 
swine. For example, the human seasonal influenza vaccine is typically a trivalent inactivated 
whole virus vaccine (Loving et al., 2013). The use of a multivalent vaccine increases the 
likelihood of protection, but the strains and the adjuvant used also play a role (Takemae et al., 
2013). If the vaccine strains do not match the current endemic viruses in a herd, the vaccine is 
unlikely to induce cross-protection. Likewise, if a poor adjuvant is used, the immune response 
will not be engaged and antibodies will not develop (Takemae et al., 2013).  
Vaccination is recommended for commercial swine, commercial birds, and humans. 
Influenza viruses can be transmitted, at least transiently, between all three species therefore the 
best control method is to prevent infection in any of the species (Thacker and Janke, 2008). In 
particular, it is recommended for animal caretakers to get routine human influenza vaccinations. 
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It is also recommended that swine herds and turkey flocks be vaccinated to prevent infection 
from  sources of wild-type IAV (Thacker and Janke, 2008).  
 
IAV Serological Overview in Swine 
 A recent meta-analysis of the swine influenza literature was performed and determined 
the average seroprevalence of IAV to be about 34.3% in US swine, which varied by year and 
location (Baudon et al., 2017). The analysis included 217 papers which represented countries 
from all continents and spanned from 1990 to the present, but only about 30 manuscripts 
represented the US (Baudon et al., 2017). This suggests there is a limited amount of serological 
investigation being performed and/or reported, which is not surprising given the difficulties of 
serological diagnostics. The first major hurdle is determining when animals are sick and need 
testing. Clinical signs are not always evident thus clinical observation is not always reliable 
(Detmer et al., 2013; Van Reeth et al., 1996). The second hurdle is the difficulty of obtaining 
serum samples, which requires a blood draw. This requires trained personnel to physically 
interact with the animals which can be problematic and time consuming (Detmer et al., 2013). 
The third hurdle is the difficulty of interpreting serological results. ELISA and HI assays can tell 
you important information about the animals tested, but only if the results are interpreted 
correctly, which is becoming more difficult as influenza becomes more genetically and 
antigenically diverse and issues with cross reactivity, or lack thereof, increase (Detmer et al., 
2013; Vincent et al., 2010). A fourth hurdle is producer non-compliance due to the perceived 
negatives of being discovered as IAV positive and the subsequent economic loss (Detmer et al., 
2013). Despite all these hurdles, a number of serological studies have been performed and the 
utility of serological assays is still important to this day. 
23 
 
 
 
North American IAV Serological Overview 
 IAV has been present in US swine herds for several decades and serological reports are 
periodically performed to evaluate seroprevalence (Baudon et al., 2017). Historically, the H1 has 
been the dominant subtype of IAV in US swineherds. According to a report from the Minnesota 
Veterinary Diagnostic Lab (MVDL), which analyzed 111,418 serum over three years, 
approximately 28.3% of swine serum from 1998 was positive for IAV antibodies and 100% of 
the antibody positive samples contained antibody against the H1 subtype (Choi et al., 2002b). In 
1999, 25.4% of serum tested at the MVDL was positive for IAV antibodies with 74.8% positive 
for the H1 subtype and 25.2% positive for the H3 subtype (Choi et al., 2002b). By 2001, 20.7% 
of swine serum tested positive for IAV antibodies with 52.6% of the positive serum samples 
reacting to the H1 subtype and 47.4% of the positive serum samples reacting to the H3 subtype 
(Choi et al., 2002b). Changes in seroprevalence could be due to both natural infection and 
increased vaccination (Choi et al., 2002b). Also it should be noted that these samples came from 
a veterinary diagnostic laboratory, thus the data generated may be biased since samples are often 
submitted because infection is suspected within a production system. Also these samples are 
voluntarily submitted and not actively collected from the field, thus the results may not represent 
the actual conditions in the field at the time this study occurred.  
 A recent study surveyed the presence of IAV in swine from the Midwest US during the 
years of 2009, 2010, and 2011 (Corzo et al., 2013). The study reported that of the 16,170 
samples collected, 746 (4.6%) were positive for IAV, which corresponded to 90.6% of farms 
testing positive for IAV (Corzo et al., 2013). Although the percentage of individual animals 
positive for IAV may appear low, the percentage of IAV positive farms is still quite high. One 
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explanation is that the increased rates of vaccination, better biosecurity, and altered management 
practices have reduced rates of infection of individual animals but has failed to eliminate IAV 
from farms completely, which persists as subclinical infections (Corzo et al., 2013). The same 
study also found that H1N1, H1N2, and H3N2 were still the predominant subtypes in US swine. 
The study also found that mixed infections with two or more IAV subtypes present on a farm 
were common (Corzo et al., 2013). This study was an active surveillance study and took samples 
from the field, but the caveat is that the study focused on grower-finisher production swine and 
not other subpopulations such a replacement gilts and sows on the breeding farm. 
Many recent US swine IAV studies, such as the one discussed above, focus on studying 
the IAV itself and how it changes over time. Often these studies use nasal swabs as the sample 
type and RT-PCR as the diagnostic test to determine whether samples are positive (Bliss et al., 
2016; Diaz et al., 2015; Kaplan et al., 2015). Nasal swabs and RT-PCR based diagnostics are 
useful because nasal swabs are easier to collect than serum samples and RT-PCR is high 
throughput and less labor intensive than most serological assays. As a result, serological studies 
are not as common in the US for commercial swine production systems.  
Canadian swineherds have also had to deal with IAV for many years. A serological study 
evaluating swine from 2001 and 2003 in Ontario using subtype specific ELISAs found that the 
seroprevalence of H1 subtype antibodies was 61.1% and 24.3% for sows and finishers, 
respectively (Poljak et al., 2008a). The seroprevalence for the H3 subtype was 0.6% and 0.7% in 
sows and finishers, respectively (Poljak et al., 2008a). A follow up study performed by the same 
authors looked at the seroprevalence during 2004 and 2005. The H1 subtype seroprevalence was 
13.4% and 14.9% for 2004 and 2005, respectively (Poljak et al., 2008b). The H3 subtype 
seroprevalence was 2.7% and 25.9% for 2004 and 2005, respectively (Poljak et al., 2008b). A 
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more recent study by the same authors looked at the seroprevalence of diagnostic cases 
submitted to the University of Guelph Animal Health Laboratory between 2007 and 2012 (Poljak 
et al., 2014). The authors evaluated the samples using subtype specific ELISAs and found that 
59.6%, 63.9%, and 48.8% of submissions were positive for the H1 subtype, H3 subtype, or both 
subtypes, respectively (Poljak et al., 2014). These studies show that IAV has been prevalent in 
Canadian swineherds. These were well thought out studies that utilized both ELISA and HI 
assays to test samples, collected samples from both finisher swine and sows, and also tried to 
account for the location and source of the animals involved. The only caveat to these studies is 
that they did not specifically try to test vaccine antigens when evaluating the antibody responses 
in the serum samples from the swine they tested. 
IAV has also been a problem for swine populations in Mexico (López-Robles et al., 
2014; Saavedra-Montañez et al., 2013). Mexican swine production is divided between large 
intensive production systems, medium sized semi-intensive production systems and small 
backyard production systems. The IAV viral ecology of Mexico is similar to the US; both 
countries are dominated primarily by classical swine H1 subtypes, but have had repeated human 
spillover strains such as human origin H3N2 and H1pdm09. A recent study, which tested over 
2000 serum samples from central Mexico over ten years from 2000-2009, found that 74% of the 
samples were positive for swine H1 subtypes, 24.2% were positive for human H3 subtypes, and 
17.8% were positive for H1pdm09 subtypes by the HI assay (Saavedra-Montañez et al., 2013). 
Another study, testing 150 serum samples from Northwestern Mexico from 2008-2009, found 
that 55% of the serum was positive for the H1 subtype and 59% of the serum were positive for 
the H3 subtype via ELISA analysis (López-Robles et al., 2014). These reports suggest a trend 
where the H1 and H3 subtypes are developing similar prevalence in Mexico. Both studies were 
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also cross-sectional and thus addressed seroprevalence within all swine subpopulations, although 
they focused on production farms and not breeding farms. 
 
Conclusions and Objectives 
 IAV is an important respiratory pathogen of swine. The virus causes respiratory illness in 
swine around the world. In the US, the viral diversity has been increasing over the last two 
decades. The introduction of the 1998 human like H3N2 and the rise of the 2009 pandemic 
H1N1 have both resulted in an explosion of viral genetic diversity. This diversity has caused 
difficulties for vaccine development as it has become difficult to create a vaccine to protect 
against all the strains of IAV present in US swineherds. Over the years, there has also been a 
decrease in serological surveillance of swineherds, which can help determine levels of 
protection. Replacement gilts in particular are a neglected subpopulation in discussion about IAV 
ecology. To help fill this gap, the following study was performed in new replacement gilts to 
evaluate the IAV antibody status in pre- and post-vaccination gilts. This study sought to evaluate 
homologous vaccine antibody responses and potential cross reactive antibodies in vaccinated 
gilts. 
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Abstract 
 The genetic diversity of influenza A virus (IAV) circulating in swine has been increasing 
over the previous twenty years. Surveillance of gilts for IAV pre- and post-vaccination antibody 
status are lacking at the farm level which may impact the health of breeding herds. This study 
sought to evaluate the IAV antibody response in breeding age, new replacement gilts prior to 
vaccination and to assess the IAV vaccine antibody response after integration into the herd. This 
study included 1,293 serum samples (504 pre-vaccination samples and 789 post-vaccination 
samples) that were collected from 12 breeding farms throughout the United States for 
approximately one year. Samples were analyzed by nucleoprotein (NP) enzyme-linked 
immunosorbent assay (ELISA) and hemagglutination inhibition (HI) assay using farm-specific 
homologous vaccine antigens and six IAV representing the predominant genetic and antigenic 
clusters circulating in swine. Approximately 38.3% (193/504) of the gilts, representing 50% 
(6/12) of the farms, were NP ELISA antibody positive prior to IAV vaccination (Pre-Vac) and 
entry into the breeding farm. Collectively, five farms lacking Pre-Vac antibodies demonstrated a 
more uniform homologous IAV vaccine antibody response. Influenza vaccines failed to induce 
HI antibodies in 100% of gilts from nine farms after receiving 4 doses of vaccine. The NP 
ELISA and HI antibodies detected on three farms using a subunit HA vaccine suggested natural 
IAV exposure occurred prior to vaccination. In summary, the IAV antibody status of 
replacement gilts can be monitored using serological assays pre- and post-vaccination which may 
help develop more effective vaccination strategies.  
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Introduction 
 Influenza A virus (IAV) is a negative sense, single stranded, enveloped, RNA virus of the 
Orthomyxoviridae family and a cause of respiratory disease in mammalian species including 
swine (Vincent et al., 2008). The three predominant IAV subtypes in swine that currently co-
circulate in the United States (US) are H1N1, H1N2, and H3N2 (Nelson et al., 2015b). IAV is 
endemic in US swine causing high morbidity but low mortality (Vincent et al., 2008). Influenza 
A virus may also result in significant economic losses to US swine producers due to decreased 
weight gain, plus increased treatment and vaccination costs (Haden et al., 2012). 
 IAV in swine are placed into multiple different phylogenetic clades based on nucleotide 
differences in the two major surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) 
(Van Reeth et al., 2012). Currently, there are sixteen IAV-S phylogenetic clades in the US. Eight 
of the genetic clades are of the H1 subtype (α, β, γ, γ2, δ-1a, δ-1b, δ-2, and pandemic 2009 
H1N1) and eight additional genetic clades are of the H3 subtype (IV, IV-A, IV-B, IV-C, IV-D, 
IV-E, IV-F, and 2010 human-like H3) (Lewis et al., 2016; Vincent et al., 2014). The antigenic 
properties of the different genetic clades within a subtype are diverse and antibody cross 
reactivity is difficult to determine without appropriate serological assays. 
 Increasing IAV-S genetic diversity has made serological surveillance and vaccination 
more difficult (Goodell et al., 2016; Sandbulte et al., 2015). Increased IAV antigenic diversity 
has complicated the interpretation of serological assays, such as the nucleoprotein enzyme-linked 
immunosorbent assay (NP ELISA) and hemagglutination inhibition (HI) assay, due to decreased 
cross reactivity and increased chances of a mismatch between test antigen and serum antibodies 
(Goodell et al., 2016; Rajao et al., 2014). Increased IAV antigenic diversity has decreased the 
ability of vaccines to broadly cross-protect against different strains of the virus and updating 
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vaccines with relevant antigens has also become more difficult  (Vincent et al., 2017). Due to the 
potential for mismatch between vaccine antigen and endemic viral strains, IAV-S vaccines need 
to be constantly evaluated and updated (Sandbulte et al., 2015). Serological tests, such as the HI 
assay, are best used for farm specific diagnostic questions such as evaluating IAV-S vaccine 
antibody responses when the previous IAV history of the farm is well-known. 
 Swine farms in the US represent dynamic production systems with individual flows of 
breeding, gestation, farrowing, nursery, grow-finish, and wean to finish farms (Knauer and 
Hostetler, 2013). Each flow or subpopulation within a farm may represent different ecological 
niches of IAV-S affecting the introduction or maintenance of new or endemic virus (Diaz et al., 
2017b). One important subpopulation is replacement gilts which may replace approximately 50% 
of the adult breeding herd per year (Penmetchsa et al., 2009). Therefore, new replacement gilts 
can impact breeding herd health in a short period of time.  
 The objectives of this study were twofold. The first objective was to characterize the IAV 
antibody status of non-vaccinated, breeding-age replacement gilts prior to entering the breeding 
farm. The second objective was to evaluate the post-vaccination, homologous vaccine antibody 
responses in new replacement gilts over their first year of residence in the breeding farm. The NP 
ELISA and HI assay were used to evaluate the pre- and post-vaccination antibody response 
during four time points over one year. Additionally, six IAV-S representing the predominant 
genetic and antigenic clusters circulating in swine were used in HI assays to evaluate the 
potential presence of pre- and post-vaccination cross reactive antibodies. Monitoring the IAV 
antibody status of new replacement gilts may justify the need to update vaccine antigens or 
adjust vaccination protocols to more effectively control IAV-S in breeding farms. 
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Materials and Methods  
Experimental Design 
 Twelve commercial breeding swine production systems (breeding farms) from eleven 
different states in the US were actively recruited for this IAV antibody study. Three farms were 
selected from each of the regions 1-4 of the United States Department of Agriculture (USDA) 
IAV-S surveillance program (USDA, 2017). The target population was non-vaccinated new 
replacement gilts prior to entry into the main breeding farm. For each farm, a minimum of 40 
serum samples were requested for the pre-vaccination (Pre-Vac) time period. The serum samples 
were randomly collected by local veterinarians and/or farm personnel. Samples were submitted 
to the Iowa State University Veterinary Diagnostic Laboratory (ISU VDL), processed via 
centrifugation at 800x g if needed, and maintained at -80°C prior to analysis. 
 During the post-vaccination time periods, a subset of 20 replacement gilts were randomly 
selected for serum collection from the initial 40 gilts. A minimum of 20 serum samples were 
requested; however, gilts may have been removed due to illness, lameness, trauma, or other 
unknown reasons thus reducing the number of samples below the target. Samples were collected 
by the veterinarian or farm personnel and the same cohort of animals were sampled at each time 
point. Samples were sent to the ISU VDL, processed by centrifugation if needed, and frozen at -
80°C to await analysis. The gilts were bled for a series of three time periods representing Post-
Vaccination (Post-Vac), Post Integration 1 (P-Int 1), and Post-Integration 2 (P-Int 2). It should be 
noted the Oklahoma (OK) herd was removed from the study due to a PRRS outbreak after the 
Pre-Vac time period. The experimental design is described in Table 1.  
 
 
40 
 
 
Farm Questionnaire  
 A questionnaire was sent to the farm veterinarians to gather gilt multiplier and breeding 
farm demographic information. Approximately eight questions focused on the gilt source and the 
sow farm demographics and included questions regarding multiplier location, influenza status of 
the multiplier site, type of multiplier, age at gilt selection, sow farm location, number of breeding 
animals, and number of replacement gilts. A second set of eight questions focused on vaccination 
protocols including vaccine platform, commercial or farm specific vaccine, number of prime and 
boost doses, timing of vaccination, isolation protocols, and gilt age at integration into the 
breeding herd. 
 
Influenza A Virus Antibody Assays 
 Serum samples were evaluated using a nucleoprotein enzyme-linked immunosorbent 
assay (NP ELISA) (Swine Influenza Virus Ab Test, IDEXX Laboratories, Inc., Westbrook, 
Maine) per manufacturer’s instructions. Briefly, serum was diluted with Dilution Solution from 
the kit to a 1:10 prior to testing and 100 µl of diluted serum were added to IAV NP-coated plates, 
incubated at room temperature for 60 minutes, washed three times with 300 µl of wash solution, 
followed by 100 µl of anti-NP conjugate, incubation at room temperature for 30 minutes, 
followed by 100 µl of TBM substrate, incubation for 15 minutes at room temp, followed by 100 
µl of stop solution. Color development was evaluated with an ELISA plate reader (Molecular 
Devices Corp., Sunnyvale, CA) at a wavelength of 650 nm to determine optical density (OD). 
One replicate per sample was used while two replicates of the positive control (PC) and negative 
control (NC) were included with each set of samples tested. To determine the validity of the the 
assay, the average OD of PC and NC were compared with an average NC value of ≥0.60 and a 
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PC/NC value of <0.50. Results were reported as a sample to negative (S/N) ratio by dividing 
sample OD by the average of the NC negative OD. Per manufacturer instructions, an S/N ratio 
≤0.60 was considered positive for IAV-S NP-ELISA antibody. An S/N ratio >0.60 was 
considered negative for IAV-S NP-ELISA antibody (Goodell et al., 2016). 
 Sera were also evaluated using a HI assay based on a previous protocol with 
modifications (Kitikoon et al., 2014). Prior to testing, sera were treated with receptor-destroying 
enzyme (RDE) (Denka Seiken., Japan) overnight at 37°C at a mixture of 1 volume serum to 4 
volumes RDE to remove non-specific inhibitors of agglutination. The following day, 5 volumes 
of 0.85% sterile saline was added to the mixture followed by heat inactivation at 56°C for 60 
minutes. Next, sera were adsorbed with 0.5 volumes of 50% turkey red blood cells (RBCs) for 
one hour, after which the serum was centrifuged at 800x g to remove the RBCs and transferred to 
a new plate. The RBC adsorption procedure was performed twice to remove natural serum 
agglutinins. Post treatment, sera were at a final dilution of 1:10 and used in HI assays with 0.5% 
turkey RBC’s as the indicator and virus antigen was diluted to 8 hemagglutination units (HAU). 
25 ul of sera were serially two-fold diluted in a V-bottom plate (Thermo Fischer Scientific, 
Rochester, New York) containing 25 ul of phosphate buffered saline (PBS) (Gibco, Grand 
Island, New York). Virus antigen at 8 HAU in 25µl was added to each dilution, incubated for 30 
minutes at room temperature, followed by the addition of 50 ul of 0.5% RBCs. After a 30 minute 
incubation, results were reported as the highest serum dilution that inhibited RBC agglutination. 
An HI titer ≥40 was considered positive, HI titers = 20 were considered suspect, and HI titers 
≤10 were considered negative. The percent HI antibody positive gilts were calculated for each 
antigen on each on farm at each time period. 
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Virus Antigens  
 Influenza A virus antigens in the HI assay were acquired from the ISU VDL or the 
United States Department of Agriculture National Veterinary Services Laboratory (USDA 
NVSL). The IAV-S were propagated in Madin-Darby Canine Kidney (MDCK) cells (ATCC 
CCL-34), clarified through centrifugation at 800x g, and analyzed for HAU as previously 
described (Kitikoon et al., 2014). Virus stocks were aliquoted in 4 ml amounts, stored at -80° C, 
and then diluted to 8 HAU prior to testing. 
 The USDA IAV surveillance data was used to select the six viruses representing the 
major genetic clades and antigenic clusters currently circulating in US swine during the 2015 
season (Abente et al., 2016; Anderson et al., 2015; Anderson et al., 2013). Three H1 and three 
H3 were chosen to evaluate the presence of cross reactive HI antibodies in the serum using the 
HI assay. The six representative antigens are further described in Table 3. 
 Sera were also evaluated in HI assays using commercial or farm-specific antigens used in 
IAV vaccines in their respective breeding farms. When possible, commercial or farm specific 
virus antigens or isolates were acquired from the ISU VDL or USDA NVSL, propagated in 
MDCK, clarified by centrifugation prior to use in the HI assay. Putative antigens were used 
when commercial vaccine or farm-specific vaccine IAV isolates were not available. Putative 
IAV antigens were chosen based on H1 amino acid sequence homology (>99.0%) with the HA1 
portion of the genome (first 200 bp of the HA) and similarity with H1 HA putative neutralizing 
epitopes, six H3 HA antigenic sites (amino acid positions 145, 155, 156, 158, 159, and 189), or 
IAV serological cross-reactivity (Abente et al., 2016; Caton et al., 1982). For the FluSure XP 
(Zoetis, Parsippany, NJ) antigens, virus isolates were unavailable and instead purified HA 
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proteins were provided by the ISU VDL and included H1-γ, H1-δ1, H1-δ2, and H3-IV. Putative 
vaccine antigens were chosen for MaxiVac Excell 5.0 (Merck Animal Health, De Soto, KS) 
based on IAV serological cross-reactivity to vaccine-specific antiserum. MaxiVac Excell 5.0 
putative vaccine antigens included A/Swine/Kentucky/02086/2008(H1-β), 
A/Swine/Ohio/02026/2008(H1-γ), A/Swine/Iowa/02955/2010(H1-δ2), and 
A/Swine/Minnesota/02782/2009(H3-IV). Maxi Vac putative antigens are further described in 
Table 3.  
 
Results 
Breeding Farm and Gilt Demographics Overview 
 The number of serum samples collected at each time period is reported in Table 1. The 
age of replacement gilts at selection or arrival to the breeding farm isolation or gilt developer 
unit (GDU) averaged twenty-four weeks old but varied based on the type of multiplication 
system (internal or external). Production systems utilizing internal multiplication selected gilts at 
a younger age than production systems that externally purchased gilts at breeding age (28-30 
weeks). Replacement gilts were sourced from an off-site location in 75% (9/12) of the sow farms 
with 44.4% (4/9) of those farms receiving replacement gilts from North Dakota (IA, IN, PA, 
ND). Approximately 41.7% (5/12) of the sow farms also reported sourcing their replacement 
gilts from known or perceived influenza negative sites (IA, IN, ND, PA, NC-1). Farm 
demographics are summarized in Table 2. 
 Ten of the eleven remaining farms enrolled in the study vaccinated their replacement 
gilts. Commercial IAV vaccines were administered in 60% (6/10) of the farms. Five farms (MO, 
NC-1, NC-2, IN, IL) used Zoetis FluSure XP
®
 and one farm (TX) used MaxiVac Excell
™
 5.0. 
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Farm-specific autogenous or custom vaccines were used in 50% (5/10) of the farms. Of the farm-
specific vaccines, NE used a bivalent vaccine, and IA and IL used a trivalent vaccine. KS used a 
quadrivalent vaccine and PA used a pentavalent vaccine. Four of the farms (IA, KS, NE, IL) 
used an HA subunit vaccine based on the replicon particle (RP) technology (Merck Animal 
Health, Madison, NJ). The IL farm switched from a commercial product to a subunit replicon 
particle vaccine (trivalent) between the P-Int 1 and P-Int 2 sample collections. The ND farm did 
not vaccinate their breeding herd.  
 Isolation protocols were used in only 36.4% (4/11) of the farms, ranging from a minimum 
of four weeks up to ten weeks, whereas 63.6% (7/11) farms did not have a specific isolation 
protocol for replacement gilts. Average gilt age at herd entry was approximately 30 weeks. 
Vaccine was administered in two doses prior to herd entry in 80% (8/10) of the farms. One farm, 
NE, administered only one dose of vaccine prior to herd entry and one farm, PA, administered 
two doses of vaccine after gilts were placed into the main breeding herd. The primary dose of 
IAV vaccine was administered approximately -10 to -4 weeks prior to placing gilts into the main 
breeding herd with the booster dose ranging from -7 to 0 weeks prior to entry. Time between 
doses, where applicable, averaged approximately 3 weeks. Farm demographic information can 
be found in Table 2. 
 
Pre-Vac Overview 
 Influenza NP ELISA antibodies were detected in 38.3% (193/504) of the gilts and 50% 
(6/12) of the farms had at least one NP ELISA positive replacement gilt. The NP ELISA 
negative farms included IA, IN, IL, NC-1, NC-2, and OK. The farms receiving NP ELISA 
positive gilts included KS, MO, ND, NE, PA, and TX. Two farms presumed to be receiving IAV 
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negative gilts, PA and ND, had 25.6% and 65.0% of the gilts test NP ELISA antibody positive, 
respectively. Conversely, NC-2, IL and OK farms presumed receiving IAV positive gilts did not 
demonstrate NP ELISA antibody positive gilts. Four of six farms with NP ELISA positive gilts 
reported internal multiplication, in contrast to four of six farms with NP ELISA negative gilts 
that reported external multiplication. Approximately 83.3% (5/6) of the farms receiving NP 
ELISA positive gilts had greater than 50% of the gilts positive for NP ELISA antibody prior to 
first vaccination. 
 Influenza HI assay antibodies to one or more representative antigens were detected in 
16.9% (85/504) of the gilts and 41.7% (5/12) farms. The farms receiving HI antibody positive 
gitls at the Pre-Vac time period included KS, MO, ND, NE, and TX. The KS and TX farms had 
62.5% (25/40) gilts test HI antibody positive to the H1-γ and 74.0% (37/50) gilts test HI antibody 
positive to the H1-δ1 representative antigens, respectively. The farms receiving HI antibody 
negative gilts to the representative antigens at the Pre-Vac time period included IA, IL, IN, NC-
1, NC-2, OK, and PA. 
 
Post-Vac Overview 
 NP ELISA antibody positive gilts were detected in 100% (10/10) of the vaccinated farms 
at Post-Vac, P-Int 1, and P-Int 2 suggesting natural exposure occurred in breeding farms using 
the subunit HA vaccine. The IN and NC-2 farms had 100% of replacement gilts test NP ELISA 
antibody positive at all three time periods; both farms used the FluSure commercial vaccine. The 
IA and KS farms did not have a single time period where 100% of replacement gilts tested NP 
ELISA antibody positive; however, both farms used subunit replicon particle vaccines. The 
percent NP ELISA positive replacement gilts ranged from 77.3% to 100% at Post-Vac, 38.1% to 
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100% at P-Int 1, and 81.8% to 100% at P-Int 2 due to vaccination or natural exposure. The 
percent NP ELISA antibody positive replacement gilts varied within and across farms and time 
periods. 
 The percent of gilts with positive homologous HI antibodies varied widely from 0.0% to 
100%, across all farms and based on vaccine type, individual vaccine antigen, and time period. 
Percent HI antibody positive Post-Vac gilts from farms using a commercial IAV vaccine ranged 
from 0% to 94.9%. The P-Int 1 and P-Int 2 percent HI antibody positive gilts in farms using 
commercial vaccines ranged from 4.3% to 100% and 18.2% to 100%, respectively. Four of five 
farms (NC-1, NC-2, IL, IN) still using commercial IAV vaccines at P-Int 2 had 100% of the gilts 
HI antibody positive to at least one antigen. However, only one farm (NC-2) at P-Int 2 had 100% 
HI antibody positive gilts to all four FluSure antigens. Most farms had at least one of the 
commercial vaccine antigens at P-Vac, P-Int 1, and P-Int 2 that did not induce an HI antibody 
response in one or more gilts. Two farms, TX and MO, had <10% of gilts demonstrate a positive 
HI antibody titer to three of their vaccine antigens after two doses of vaccine at the P-Vac time 
point. Percent positive gilts with HI antibody titers remained low, 4.3% to 54.5%, for the H1 
vaccine antigens throughout all time periods in the MO farm.  
 Breeding herds using farm specific IAV antigens demonstrated a similar level of 
variability in the percent positive replacement gilts within and across farms. The percent positive 
gilts with HI antibody titers from herds using farm specific antigens ranged from 0.0% to 85.3% 
at P-Vac, 0.0% to 85.7% at P-Int 1, and 0.0% to 100% at P-Int 2 across all antigens. The four 
farms that used a farm specific IAV vaccine had at least one or more antigens that were unable to 
induce a positive HI antibody titer in >50% of the gilts at P-Vac after receiving two doses of 
vaccine, including the NE gilts although they received only one dose of vaccine. Three farms had 
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at least one antigen in their farm specific vaccine that failed to induce a positive HI antibody titer 
in at least 50% of the gilts at P-Vac, P-Int 1, or P-Int 2. The KS farm had one antigen (2014 H1- 
δ2) that was unable to detect a positive HI antibody response in any of the gilts across all time 
points.  
 The percent HI antibody positive gilts to the six representative antigens was highly 
variable post vaccination and obvious trends were not observed. Percent positive gilts ranged 
from 0% to 100% based on representative antigen, farm, and time period. Cross reactivity was 
difficult to predict as some farms displayed HI antibody positive gilts to representative antigens 
that were of the same phylogenetic cluster as the vaccine antigens while some farms did not. In 
addition, 7 of the 10 vaccinated farms displayed >50% of gilts testing positive to a representative 
antigen from a cluster that was not included in the vaccine. An example is the IA farm which 
displayed >60.0% HI antibody positive gilts to the H3-Green representative antigen at Post-Vac, 
P-Int 1, and P-Int 2, despite the vaccine administered not containing an H3-Green (H3-IVA) 
antigen. Since each farm presented different pre- and post-antibody statuses and there were no 
general trends among all farms, we next evaluated the responses individually by farm. 
 
Gilts without pre-vaccination IAV antibodies responded more uniformly to vaccine 
The NC-2 farm is an example of how serologically negative gilts can have a more 
uniform IAV vaccine response. The NC-2 farm used the FluSure commercial product, externally 
purchased their replacement gilts from Mississippi, and reported that their multiplier source was 
IAV positive (Table 2). Reviewing the Pre-Vac data, none of the new replacement gilts from the 
NC-2 farm tested NP ELISA antibody positive at the Pre-Vac time period although the status of 
the multiplier may have been IAV positive (Figure 1A). The NC-2 gilts also tested HI antibody 
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negative to all six of the representative antigens in the HI Assay (Figure 1B). These results 
suggest a lack of recent exposure in these gilts and/or waning of maternal antibodies below the 
level of detection by the assay. 
Naïve gilts from the NC-2 farm administered the commercial FluSure vaccine 
demonstrated an adequate Post-Vac HI antibody response, overall. The replacement gilts 
received two doses of vaccine prior to serum collection at Post-Vac. Testing with homologous 
HI vaccine antigens demonstrated >69.0% of the gilts HI antibody positive to three of the four 
vaccine antigens (Figure 1A). The fourth antigen had a reduced number of positive gilts at 
27.8%. After a third dose of vaccine at the P-Int 1 time period, >96.0% of the replacement gilts 
were HI antibody positive to all four vaccine antigens. The percentage of HI antibody positive 
gilts increased to 100% for all antigens by the P-Int 2 time period. This suggests that 3 doses of 
FluSure induced a more uniform HI antibody response in naïve gilts based on the vaccination 
protocol specific to the farm. 
 The NC-2 farm displayed a number of gilts with cross reactive antibodies to the 
representative virus antigens. At Post-Vac, >50.0% of the gilts tested positive to both the H1-δ1 
and H1-δ2 representative antigens. By P-Int 2, >95.0% of gilts tested HI antibody positive to the 
H1-γ, H1-δ1, and H1-δ2 representative antigens (Figure 1B). This is was expected since the 
FluSure vaccine contains H1-γ, H1-δ1, and H1-δ2 vaccine antigens suggesting the representative 
antigens may have been antigenically similar to the vaccine strains. Additionally, ≥50.0% of the 
gilts were HI antibody positive to the H3-Red representative antigen, starting in the Post-Vac 
time period, and the H3-Green representative antigen, starting in the P-Int 1 time period. This is 
could represent a potential novel IAV infection since the antigenic properties of the FluSure 
vaccine H3 component are unknown. 
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NP ELISA positive gilts at vaccination demonstrated reduced HI antibody responses to vaccine 
antigens  
 The MO farm is an example of how IAV antibody positive gilts may respond 
immunologically to inactivated, whole virus IAV vaccination, using the NP ELISA and HI assay. 
The MO farm also used the FluSure commercial product, externally purchased their gilts from 
Illinois, and reported their multiplier location was positive for IAV (Table 2). At the Pre-Vac 
time period, 87.5% of the new replacement gilts tested NP ELISA antibody positive (Figure 1C). 
This suggests natural IAV exposure or residual passive antibodies within this population of 
replacement gilts considering gilts were not IAV vaccinated prior to analysis. This was further 
supported by the detection of cross reactive HI antibodies to one or more of the six representative 
antigens. Specifically, 22.5% and 12.5% of the gilts tested HI antibody positive for the H3-Green 
and H3-human like representative antigens, respectively (Figure 1D). 
 The MO farm gave two doses of the FluSure vaccine prior to serum collection for the 
Post-Vac time period. In sharp contrast to the NC-2 antibody negative herd, none of the gilts 
tested HI antibody positive to the three H1 vaccine antigens, suggesting vulnerability to an H1 
IAV infection during this time period. The percentage of positive gilts to the H1 vaccine 
components increased at the P-Int 1 time period after receiving a third dose, with 21.7%, 13.0%, 
and 4.0% of the gilts testing HI antibody positive for the H1-γ, H1-δ2, and H1-δ1 vaccine 
antigens, respectively. By the P-Int 2 time period the percentage of HI antibody positive gilts for 
the H1 subtype antigens were only 45.5%, 54.5%, and 18.2% for the H1-γ, H1-δ2, and H1-δ1 
vaccine antigens, respectively. The H3 response was impacted to a lesser degree, as 65.6% of the 
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gilts tested HI antibody positive to the H3-IV vaccine antigen at the Post-Vac time period and 
increased to 78.3% and to 81.8% at P-Int 1 and P-Int 2, respectively. 
 The MO farm had low levels of cross reactive antibodies to the six representative 
antigens. With the exception of the H3-Green and H3-human like representative antigens, cross 
reactive antibodies were <37% for all antigens at all time periods (Figure 1D). At P-Int 1, 78.3% 
and 60.9% of gilts on the MO farm tested HI antibody positive to the H3-Green and H3-human 
like representative antigens. By P-Int 2, 95.5% of gilts tested HI antibody positive to the H3-
Green representative antigen, which could be due an ongoing novel infection with an H3-Green 
virus that does not cross react with the FluSure H3 component. The results are unclear as the 
antigenic properties of the FluSure H3 component are unknown. 
 
Post vaccination NP ELISA positive gilts suggests natural exposure on farms using an HA 
subunit vaccine 
 The IA farm was an example of a farm where IAV natural infection likely occurred based 
on the NP ELISA and HI assay data. The IA farm used a trivalent, farm specific subunit HA 
replicon particle vaccine, purchased their replacement gilts from an external source in North 
Dakota, and reported the multiplier location was IAV negative (Table 2). The vaccine contained 
an H1-γ, H1-δ1, and H3-human like HA RNA components (Table 3). Since the replicon particle 
vaccine did not include an NP RNA component, an NP antibody response post vaccination is 
suggestive of natural exposure. None of the replacement gilts from the IA farm tested NP ELISA 
antibody positive at the Pre-Vac time period, yet >97.1% of gilts tested NP ELISA antibody 
positive at the Post-Vac time period following integration into the breeding herd (Figure 2A). 
The percentage of NP ELISA antibody positive gilts remained high throughout the time periods 
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with 74.3% and 86.5% of gilts NP ELISA antibody positive at the P-Int 1 and P-Int 2 time 
periods, respectively.  
 The vaccine antibody response was variable between the different antigens within the 
vaccine, as measured by the percent HI antibody positive gilts. The H1-δ1 antigen had the most 
robust response with >85.0% of the replacement gilts testing HI antibody positive at all time 
periods. The H1-γ antigen had a lower response with only 26.5% of gilts testing HI antibody 
positive at Post-Vac and rising to 67.6% of gilts testing HI antibody positive at P-Int 2. The H3-
human like antigen had a poor response with <28% of gilts testing HI antibody positive at all 
time periods. While the vaccine antibody response was variable by antigen, antibody responses 
to all antigens increased over time. 
 The NP ELISA antibodies suggest natural infection, and a large percentage of the 
replacement gilts from the IA farm had cross reactive antibodies to the representative antigens. 
The vaccine used did not contain an H3-Green (H3-IVA) antigen, yet 61.8% of the replacement 
gilts tested HI antibody positive to the H3-Green representative antigen at the Post-Vac time 
period (Figure 2B). The percentage of HI antibody positive gilts to the H3-Green representative 
antigen continued to increase to 82.9% and 97.3% for the P-Int 1 and P-Int 2 time periods, 
respectively. There was also evidence of natural infection due to an H1-δ2 strain of IAV. At the 
P-Int 2 time period, 100% of replacement gilts tested HI antibody positive to the H1-δ2 
representative antigen (Figure 2B). Less than 3% of the gilts tested HI antibody positive to the 
H1-δ2 representative antigen prior to the P-Int 2 time period. 
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NP ELISA and HI antibodies waned without further boosting in a negative sow herd 
 The North Dakota farm reported that they did not vaccinate their new replacement gilts, 
internally produced their gilts, and that their multiplication site was influenza negative. However, 
the NP ELISA and HI assay results indicate the gilts were exposed prior to entering the breeding 
herd. At the Pre-Vac time period, 65.0% of the replacement gilts tested NP ELISA antibody 
positive and 22.5% of replacement gilts tested HI antibody positive to the H3-human like 
representative antigen (Figure 2C). This suggests possible IAV exposure in these gilts despite the 
farm presumption that the multiplier site was IAV negative. The antibody assays cannot rule out 
human seasonal H3 exposure or exposure to the 2010 hu-like H3N2 currently circulating in the 
US swine population (Rajão et al., 2015). The observed Pre-Vac antibody responses waned by 
the Post-Vac time period, suggesting that IAV was circulating at a low prevalence or not at all in 
the main breeding herd and additional exposure to human-seasonal H3 was lacking. All 
replacement gilts were NP ELISA antibody negative at Post-Vac, P-Int 1, and P-Int 2. Also, all 
replacement gilts were HI antibody negative for cross reactive antibodies to the H3-human like 
representative antigen at Post-Vac, P-Int 1, and P-Int 2. These data suggest that IAV antibody 
wanes quickly unless boosted by natural infection or vaccination and that negative sow farms 
may be at risk for human seasonal or swine-origin IAV infection.  
 
Discussion  
Epidemiological studies of IAV in swine reported in the literature frequently focus on 
detecting and sequencing virus (Corzo et al., 2013; Diaz et al., 2017a; Diaz et al., 2017b). 
Serological surveillance has often targeted adult breeding swine or slaughter pigs but few 
replacement gilts (Kyriakis et al., 2013; Van Reeth et al., 2008). The aim of the current study 
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was to evaluate the IAV antibody status of non-vaccinated, new replacement gilts prior to 
vaccination and following entry into a breeding herd. Post vaccination and post entry and into a 
breeding herd IAV antibody responses were evaluated using homologous vaccine antigens and 
six representative antigens representing dominant IAV circulating in the swine population 
identified by USDA surveillance. The initial pre-vaccination serum samples were collected at 
approximately 24 weeks of age, and were evaluated for the presence of IAV antibodies using the 
NP ELISA and HI assay using six representative antigens. The post vaccination serum samples 
were collected at three time periods over one year, from a subset of the initial set of gilts, and 
tested for IAV antibodies using the NP ELISA and HI assay with homologous vaccine antigens 
and six representative antigens. 
 Endemic IAV infections are common in breeding herds in the US, although many remain 
undiagnosed because clinical signs are mild and diagnostic tests, such as serological assays, are 
not performed routinely (Simon-Grifé et al., 2012; White et al., 2017). In our study, 58.3% (7/12) 
of the farms enrolled reported sourcing their gilts from IAV positive multiplication sites. It is 
unclear if the IAV status was based solely on observed clinical disease or diagnostic testing. In 
either case, it appears diagnostic testing was under-utilized since two farms (ND and PA) 
reported sourcing their new replacement gilts from an IAV negative multiplier yet >20% of their 
gilts tested IAV antibody positive. Additionally, three farms (NC-2, IL, and OK) reported 
sourcing their gilts from IAV positive sites were instead IAV antibody negative at Pre-Vac. This 
demonstrates the importance of conducting serological testing on new replacement gilts to more 
accurately determine IAV antibody profiles. 
 Knowledge of replacement gilt IAV anybody status is important considering pre-existing 
IAV antibody may influence vaccine antibody responses and there are efforts to maintain IAV 
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free replacement gilts within the swine industry (Corzo et al., 2014). Vaccinating serologically 
negative gilts may be preferential to avoid maternal antibody and/or prior immunity interference. 
In contrast, IAV antibody negative gilts may be vulnerable to natural infection from nearby 
farms or endemic strains when they are integrated into the breeding farm (Poljak et al., 2008). 
An example of how IAV antibody negative gilts respond effectively to vaccination was 
demonstrated in the NC-2 farm, where all gilts were NP ELISA and HI antibody negative at Pre-
Vac. Upon vaccination, there were HI antibody responses in >69.0% of the gilts against three of 
the four vaccine antigens. By the P-Int 2 time period, 100% of the gilts tested were HI antibody 
positive to all four of the vaccine antigens. Although the ideal response would be 100% positive 
to all 4 antigens after 2 doses, compared to farms that vaccinated IAV antibody positive gilts, the 
results from this farm provided evidence that vaccinating serologically negative gilts was 
beneficial and yielded a stronger antibody response. 
The MO farm utilized the same vaccine as the NC-2 farm, but was an example of how 
pre-existing antibodies may interfere with vaccine antibody responses (Fazekas de St Groth and 
Webster, 1966; Fonville et al., 2016; Vincent et al., 2017). At the Pre-Vac time period, 87.5% of 
the replacement gilts tested NP ELISA antibody positive and 22.5% tested HI antibody positive 
to the H3-Green (H3-IVA) representative antigen. Taken together, the assay results suggest that 
there was significant IAV exposure prior to the Pre-Vac time period, including but not limited to 
a virus of the H3-green antigenic cluster. The pre-existing antibodies may have interfered with 
the vaccine antibody response since none of the replacement gilts tested HI antibody positive for 
the three H1 subtype vaccine antigens (H1-γ H1-δ1, and H1-δ2) at the Post-Vac time period. The 
antibody response continued to be muted to the test antigens through the P-Int 2 time period with 
<55% of the gilts testing HI antibody positive against the H1-subtype vaccine antigens. The MO 
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farm shows the impact that pre-existing IAV antibodies can have on vaccine antibody responses 
in replacement gilts. 
 The IA farm is an example of the utility of the NP ELISA and HI assays used in 
combination to differentiate natural infection from vaccination. The IA farm used a RP vaccine, 
which delivers RNA for the HA protein to host cells, thus it should not induce an NP antibody 
response (Vander Veen et al., 2012). This allows for the NP ELISA to potentially evaluate 
endemic infection within a breeding herd that uses an RP vaccine. None of the new replacement 
gilts from the IA herd tested NP ELISA or HI antibody positive at the Pre-Vac time period. 
However, after entry to the breeding herd and vaccination, 97.1% of replacement gilts tested NP 
ELISA and HI antibody positive to the H3 hu-like representative antigen as well as 61.8% testing 
HI antibody positive to the H3-Green representative antigen. These results suggest that a 
potential natural exposure to an H3-human like and H3-Green (H3-IVA) may have occurred 
between the Pre-Vac and Post-Vac sample collection time periods. There was also evidence for 
interference with the hu-like H3 component of the vaccine since only 2.9% of the replacement 
gilts tested HI antibody positive to the H3-human like vaccine antigen. Potentially, antibody 
blunting may have occurred due to the two viruses being homosubtypic and antigenically similar 
and as a result the previous exposure could have prevented the immune system from recognizing 
the vaccine antigen and thus the immune system did not mount a novel antibody response, but 
further testing comparing the two viruses genetically and antigenically would need to be 
performed. At P-Int 2 the percentage of NP ELISA positive replacement gilts was still high at 
86.5% of gilts, which was suggestive of continued endemic circulation of IAV within the herd. 
The HI assay data supports that a second virus of the H3-Red antigenic cluster may have entered 
the breeding herd at P-Int 1 with 57.1% of gilts testing HI antibody positive and that a H1-δ2 
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may have also entered the breeding herd at P-Int 2 with 100% of the replacement gilts testing HI 
antibody positive. The IA herd shows how the NP ELISA and HI assay can be used to determine 
potential endemic viral infections on farms that use a replicon particle vaccine and help 
producers formulate changes to their vaccine products and vaccination protocol. 
 The ND farm provided another example of the importance of serological surveillance that 
combines NP ELISA and HI assays. The ND farm self-reported as maintaining an IAV negative 
breeding herd and gilt multiplier. The farm is located in a low swine dense area of the US, 
produce their gilts internally, and do not purchase external gilts. However, 65.0% of the 
replacement gilts tested NP ELISA antibody positive at Pre-Vac. Additionally, 22.5% of the 
replacement gilts tested HI antibody positive to the H3-human like representative antigen. This 
exposure could have been due to either a contemporary human seasonal H3N2 from infected 
farm workers or to the currently endemic 2010 hu-like H3 swine virus. Human seasonal 
spillovers into swine are not uncommon, but human viruses often fail to transmit onward to 
become established in swine (Nelson et al., 2015a; Nelson and Vincent, 2015). This may have 
been the case as by the Post-Vac time period, as none of the replacement gilts tested NP ELISA 
antibody positive or HI antibody positive to the H3 hu-like representative antigen. Additionally 
these data suggest that IAV antibodies quickly waned, within 6-8 weeks, to undetectable levels 
without a stimulating exposure; either natural infection or vaccination. This data supports the 
importance of routinely performing diagnostic serologic testing rather than assuming serological 
status based on previous history. 
 Collectively, the data from this study demonstrates the importance of serological testing 
to confirm the status of new replacement gilts entering the breeding farm as IAV negative or 
with evidence of prior exposure to endemic IAV present at the genetic multiplier. Replacement 
57 
 
 
gilts that are IAV antibody negative may be advantageous since they are less likely to transmit 
new viruses to breeding farm and are more likely to have a robust vaccine antibody response to 
the vaccines used on the breeding farm. However, antibody negative gilts may be vulnerable to 
exposure to endemic IAV in the main breeding herd if exposure occurs within the first weeks of 
being on a production site prior to induction of immune responses to inactivated IAV vaccines. 
Naïve or partially immune incoming gilts may thus help maintain endemic infections within a 
breeding farm. Increased IAV serological monitoring of replacement gilt populations can help 
identify exposure history and/or residual passive antibody, therefore help develop new 
vaccination protocols or improve the timing of existing vaccination protocols to maximize 
antibody responses, and ultimately determine the best strategy for introducing replacement gilts 
to the adult breeding herd. Several of the farms tested in our study may have benefitted from 
beginning vaccination regimens in gilts several weeks before the initiating dose in their current 
protocols, or vaccinating at the multiplier site, in order to maximize the vaccine response to all 
antigens contained in the multi-valent vaccines. Replacement gilts play a significant role in 
affecting the overall health of the breeding herd and serological monitoring utilizing both NP 
ELISA and HI assays to evaluate IAV antibody status can help reduce the propagation of new 
and endemic IAV in the breeding herd. 
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Table 1: Experimental design and serum sample collection schedule. 
Population location Group Mean #. of 
samples per 
farm
a*
  
Total # of 
samples 
Gilt age or 
category 
Time between 
vaccine & 
collection 
Time 
frame
b†
 
GDU
c‡
/Isolation/Acclimation Pre-Vac 42 (40-50) 504 20-28 weeks N/A Oct 2015 - 
Jan 2016 
GDU/Isolation/Gestation Post-Vac 30 (20-44) 325 28-32 weeks 2-4 wks post vac Dec 2015 - 
Jul 2016 
Breeding Herd Post-Int 1 23 (14-35) 251 Parity 1 4-6 wks post vac Mar 2016 - 
Dec 2016 
Breeding Herd Post-Int 2 20 (7-37) 213 Parity 2 4-6 wks post vac Sep 2016 - 
Mar 2017 
*: Mean number and range of serum samples collected from gilts per farm. 
†: Time range when sample collection occurred.  
‡: Gilt developer unit. 
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Table 2: Farm demographic information organized into Gilt Source, Sow Farm, and Vaccination demographics 
    Gilt Source Demographics  Sow Farm Demographics  Vaccination Demographics 
Region N Sow  
Farm  
State 
 State Multiplication IAV  
status 
 Population  
- sows 
Population  
- gilts 
Age*  Isolation  
protocol 
Vaccine 
 antigen 
Vaccine  
Type 
Age at  
Entry to  
Breeding herd† 
#  of  
Doses 
Time of  
vaccination‡ 
1 40 PA  ND External Offsite Negative  1550 650 24  None Farm- 
specific 
Whole  
virus 
24-26 2 0 & +2  
weeks§ 
 50 NC-1  VA External Offsite Negative  3696 814 28  None FluSure XP® Whole  
virus 
32 2 -6 & -4  
weeks 
 41 NC-2  MS External Offsite Positive  3085 872 25  None FluSure XP® Whole  
virus 
30-32 2 -5 & 0  
weeks 
                   
2 43 IA  ND External Offsite Negative  2800 375 21  8-10 weeks Farm- 
specific 
Subunit 30 2 -6 & -4  
weeks 
 40 IN  ND External Offsite Negative  1600 300 24  4 weeks FluSure XP® Whole  
virus 
28 2 -4 & -1  
weeks 
 40 IL  IL Internal Onsite Positive  5800 800 20  8 weeks FluSure XP® Whole  
virus 
30 2 -7 & 0  
weeks 
                   
3 40 OK  OK Internal Offsite Positive  63000 3150 20  N/A N/A N/A N/A N/A N/A 
 50 TX  TX Internal Onsite Positive  1984 1280 28  None MaxiVac  
Excell™ 
Whole  
virus 
30-32 2 -4 & 0  
weeks 
 40 MO  IL External Offsite Positive  2360 185 23  8 weeks FluSure XP® Whole  
virus 
30-32 2 -7 & -3  
weeks 
                   
4 40 KS  KS Internal Offsite Positive  1250 145 24  None Farm- 
specific 
Subunit 33 2 -9 & -6  
weeks 
 40 NE  NE Internal Offsite Positive  5600 300 22  None Farm- 
specific 
Subunit 26 1 -4  
weeks 
 40 ND  ND Internal Onsite Negative  4000 400 26  N/A N/A N/A 26 N/A N/A 
*: Age in weeks at sample collection 
†: Age at herd entry in weeks. 
‡: Timing of vaccination relative to entry into the main breeding herd (0 weeks). 
§: Vaccine administered post-entry into the herd. 
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Table 3: Influenza A Viruses used for Representative Antigens, Homologous Vaccine 
Antigens, and Putative Vaccine Antigens for HI assay testing 
 Subtype Reference Year Virus Cluster/Clade GenBank No. 
Representative  
antigens 
H1N1 H1-γ 2007 A/Swine/Ohio/511445/2007 Gamma EU604689 
H1N2 H1-δ1b 2013 A/Swine/South Dakota/A01349341/2013 Delta-1b KC844209.1 
H1N1 H1-δ2 2005 A/Swine/Illinois/00685/2005 Delta-2 CY081899.1 
H3N2 H3 Red 2011 A/Swine/New York/A01104005/2011 Cluster IVA JN940422.1 
H3N2 H3-Green 2014 A/Swine/Iowa/A01480656/2014 Cluster IVA KJ635928.1 
H3N2 H3 hu-like 2014 A/Swine/Missouri/A01410819/2014 2010 human-like KJ941380.1 
       
FluSure XP 
 Vaccine 
 Antigens 
H1N1 H1-γ 2008* FluSure XP 012 Gamma N/A 
H1N2 H1-δ1 2008* FluSure XP 726 Delta-1 N/A 
H1N1 H1-δ2 2008* FluSure XP 031 Delta-2 N/A 
H3N2 H3-IV 2011* FluSure XP 069 Cluster IV N/A 
       
MaxiVac  
putative  
vaccine  
antigens 
H1N1 H1-β 2008 A/Swine/Kentucky/02086/2008 Beta N/A 
H1N1 H1-γ 2008 A/Swine/Ohio/02026/2008 Gamma N/A 
H1N2 H1-δ2 2010 A/Swine/Iowa/02955/2010 Delta-2 N/A 
H3N2 H3-IV 2009 A/Swine/Minnesota/02782/2009 Cluster IV N/A 
       
IA farm  
putative  
vaccine  
antigens 
H1N2 H1-δ1 2013 A/swine/Illinois/A01291356/2013 Delta-1 AGX00886.1 
H1N1 H1-γ 2014 A/swine/Iowa/A01410104/2014 Gamma KJ437539.1 
H3N2 H3 hu-like 2015 A/swine/Iowa/A02076444/2015 Human like KR812416.1 
       
KS farm  
putative  
vaccine  
antigens 
H1N1 H1-γ 2011 A/swine/Indiana/41733/2011 Gamma N/A 
H1N2 H1-δ2 2014  A/swine/Missouri/A01411322/2014 Delta-2 KJ437545.1 
H3N2 H3-IV 2009 A/swine/Minnesota/02782/2009 Cluster IV N/A 
H1N1 H1-pdm09 2009 A/California/04/2009 Pandemic 2009 N/A 
       
PA farm  
vaccine  
antigens 
H1N1 H1-γ 2013 A/swine/Ohio/47242/2013 Gamma N/A 
H1N1 H1-δ1 2012 A/swine/Indiana/2012 Delta-1 N/A 
H1N2 H1-δ2 2015 A/swine/Pennsylvania/16577/2015 Delta-2 N/A 
H3N2 H3-IV 2015 A/swine/19299/2015 Cluster IV N/A 
H3N2 H3-IVB 2015 A/swine/Michigan/18353/2015 Cluster IVB N/A 
       
NE farm  
putative  
vaccine  
antigens 
H1N1 H1-δ2 2014 A/swine/North Carolina/A01477778/2014 Delta-2 KP186042.1 
H1N1 H1-pdm09 2014 A/swine/Kansas/A01410327/2014 Pandemic 2009 KJ605091.1 
       
IL farm  
vaccine  
antigens 
H1N1 H1-pdm09 2016 A/swine/Illinois/A01729364/2016 Pandemic 2009 KU598287.1 
H1N2 H1-δ1 2015 A/swine/Illinois/A01797385/2015 Delta-1 KU301001.1 
H3N2 H3 hu-like 2015 A/swine/Missouri/61110/2015 Human like N/A 
*: Dates are based on when Zoetis distributed the antigens to the ISU VDL for use in 
diagnostic testing. According the ISU VDL, all antigens are currently used in the vaccine 
product.  
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Figure 1: Graphs of the Percent NP ELISA Antibody Positive and Percent HI Antibody 
Positive Replacement Gilts at Pre-Vac, Post-Vac, P-Int 1, and P-Int 2 to Homologous 
Vaccine Virus Antigens (A, C) and Six Representative Virus Antigens (B, D) for the NC-2 
(A, B) and MO (C, D) farms. Note both farms used the FluSure vaccine. 
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Figure 2: Graphs of the Percent NP ELISA Antibody Positive and Percent HI Antibody 
Positive Replacement Gilts at Pre-Vac, Post-Vac, P-Int 1, and P-Int 2 to Homologous 
Vaccine Virus Antigens (A) and Six Representative Virus Antigens (B) for the IA (A, B) 
farm. Note the IA farm used a subunit HA replicon particle vaccine. 
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Figure 3: Graphs of the Percent NP ELISA Antibody Positive and Percent HI Antibody 
Positive Replacement Gilts at Pre-Vac, Post-Vac, P-Int 1, and P-Int 2 to Six Representative 
Virus Antigens for the ND farm. Note the ND farm did not vaccinate. 
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Figure S1: Graphs of the Percent NP ELISA Antibody Positive and Percent HI Antibody 
Positive Replacement Gilts at Pre-Vac, Post-Vac, P-Int 1, and P-Int 2 to Homologous 
Vaccine Virus Antigens (A) and Six Representative Virus Antigens (B) for the TX (A, B) 
farm. Note the TX farm used the MaxiVac Excel vaccine. 
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Figure S2: Graphs of the Percent NP ELISA Antibody Positive and Percent HI Antibody 
Positive Replacement Gilts at Pre-Vac, Post-Vac, P-Int 1, and P-Int 2 to Homologous 
Vaccine Virus Antigens (A, C) and Six Representative Virus Antigens (B, D) for the IN (A, 
B) and NC-1 (C, D) farms. Note both farms used the FluSure vaccine. 
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Figure S3: Graphs of the Percent NP ELISA Antibody Positive and Percent HI Antibody 
Positive Replacement Gilts at Pre-Vac, Post-Vac, P-Int 1, and P-Int 2 to Homologous 
Vaccine Virus Antigens for FluSure (A) and Farm Specific (B) plus Six Representative Virus 
Antigens (C) for the IL (A, B, C) farms. Note the IL farm switched from FluSure vaccine to 
Farm Specific vaccine between P-Int 1 and P-Int 2.   
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Figure S4: Graphs of the Percent NP ELISA Antibody Positive and Percent HI Antibody 
Positive Replacement Gilts at Pre-Vac, Post-Vac, P-Int 1, and P-Int 2 to Homologous 
Vaccine Virus Antigens (A, C) and Six Representative Virus Antigens (B, D) for the NE (A, 
B) and KS (C, D) farms. Note both farms used a subunit HA replicon particle vaccine. 
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Figure S5: Graphs of the Percent NP ELISA Antibody Positive and Percent HI Antibody 
Positive Replacement Gilts at Pre-Vac, Post-Vac, P-Int 1, and P-Int 2 to Homologous 
Vaccine Virus Antigens (A) and Six Representative Virus Antigens (B) for the PA (A, B) 
farm. Note PA farm used a farm specific whole inactivated virus vaccine. 
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CHAPTER 4. SUMMARY AND CONCLUSIONS 
 
The objective of this project was to determine the serological status of new 
replacement gilts pre- and post- vaccination. This goal was accomplished by enrolling twelve 
farms from across the United States into the study. Serum was collected at four time points 
from the same subpopulation of replacement gilts on each farm. Antibody response was 
evaluated using the Nucleoprotein Enzyme-linked Immunosorbent Assay (NP ELISA) and a 
Hemagglutination Inhibition (HI) Assay using homologous vaccine antigens and six H1 and 
H3 antigens representing the predominant phylogenetic clusters and antigenic clades 
circulating in US swine. 
The literature review chapter for this thesis revealed two important gaps in our 
knowledge of IAV in swine. First, there was a lack of recent IAV serological data on swine 
in the US. Serological studies have been conducted previously, but are considered historic 
and may lack data relevant to contemporary IAV in swine. Current epidemiological 
evaluations of IAV in US swine have focused on virus isolation and characterization of the 
genetic and antigenic diversity. Second, there is a lack of IAV information regarding new 
replacement gilts within US production systems. The majority of scientific studies focus on 
mature sows, nursing piglets, or finisher swine when evaluating disease dynamics. New 
replacement gilts appear to be an understudied group. This thesis sought to address both 
knowledge gaps by targeting new replacement gilts to evaluate their IAV antibody status 
during a critical time in their development and preparation to enter the breeding farm. 
Chapter 3 and 4 detail the results from the serological evaluation of new replacement gilts 
divided into pre- and post-vaccination data, respectively. 
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Chapter 3 pre-vaccination data suggested the IAV dynamics of the multiplication or 
source herd may determine the IAV antibody status of new replacement gilts. Additionally, 
the data demonstrated a number of new replacement gilts are entering the farm IAV antibody 
naïve, which could leave them susceptible to resident endemic viruses and contribute to 
maintenance of endemic infections. Increased IAV antibody surveillance of replacement gilts 
could improve the ability of breeding farms to adequately prepare gilts to enter the breeding 
herd. Care should be taken when choosing a serology test and interpretation of the data due 
to the increased genetic diversity of IAV-S in US swine and how that can affect test 
outcomes. The NP ELISA is the preferred diagnostic assay for evaluating potential IAV 
exposure. 
The post-vaccination data demonstrated the number of IAV antibody positive gilts is 
variable across farms and over time regardless of using commercial or farm specific 
vaccines. Several farms had gilts without detectable IAV antibody responses or low numbers 
of gilts with homologous IAV positive HI antibody titers even after multiple doses of 
vaccine. This lack of antibody response suggests a gap in protection based on the assays 
performed. The data also revealed the potential limitations of the antibody assays. The HI 
assay is a powerful tool for evaluating homologous vaccine responses and correlates with 
protection, and works well to evaluate cross-reactive heterologous antibody responses if the 
antisera and antigen have been characterized. The NP ELISA can be an excellent tool for 
evaluating potential IAV exposure but is unable to detect certain types of vaccine platforms 
(for example, replicon particle vaccines) and does not correlate with protection. Vaccination 
of breeding age gilts is important for inducing maternal antibodies to protect suckling piglets. 
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Increased antibody surveillance is recommended to help monitor IAV vaccine immune 
responses as well as potential cross-reactive antibody that may be present in breeding gilts. 
Collectively, it can be concluded from this thesis that IAV vaccine antibody 
responses in the field are highly variable, unpredictable with diagnostic assays, and require 
increased surveillance to ensure protective levels are maintained. If the results of this thesis 
are reflective of the swine industry as a whole, then changes in vaccination protocols could 
be considered. The update of current vaccines with contemporary viruses or the adoption of 
novel vaccine platforms may help increase protection in US swineherds. Regardless of any 
changes made to vaccination protocols, increased serological surveillance would help the 
industry. Increased surveillance would help identify gaps in protection and allow for the 
evaluation of any changes to vaccination protocols.  
There are a number of possible future projects based on the results of this thesis. One 
line of future work could be going back and reevaluating some of the serum from some of the 
more interesting farms. The North Dakota herd was located in a region with low-density of 
swine and did not vaccinate their swine, yet there were a large number of NP ELISA positive 
animals and several samples tested HI antibody positive for the H3hu-like representative 
antigen. It would be interesting to go back and retest the serum with additional representative 
viruses such as more swine H3 hu-like viruses and some human seasonal H3 IAV. This 
additional testing could help investigate if a human virus infected swine. A second avenue of 
future research could be performing a second longitudinal study and combine virological and 
serological methods. Another set of farms could be sampled over a year and oral fluids or 
nasal swabs could be collected in addition to serum samples. Utilizing virology tests, such as 
virus isolation and sequencing could be performed in addition to serological testing. This 
76 
 
 
would allow for the correlation of viral infection and antibody profile and we could examine 
how effective vaccination is at preventing endemic viral circulation.  
 
 
